News RELAY MEDICAL AND SWISS PHARMACAN AG ANNOUNCE INITIAL GLOW LIFETECH PRODUCT LINE
Relay Medical Corp. has provided an update on the Glow LifeTech Ltd. joint venture subsidiary and initial product line.
In early March, Relay Medical announced the signing of an agreement whereby Glow LifeTech would acquire the exclusive North American rights for the manufacturing and sales of MyCell Inside advanced encapsulation technology from Swiss PharmaCan AG for cannabinoids and select nutraceuticals. As Glow, the companies will maintain a continuing, collaborative working relationship, providing support with continiung studies, regulatory approvals and access to a pipeline of future product innovations.
"We are ecstatic to bring initial product lines to market in partnership and with the support of the leading-edge operation in Switzerland," said Yoav Raiter, chief executive officer, Relay Medical. "The technology that will be in our products is of a quality that health-conscious consumers deserve. When you can try it for yourself, and I hope you will, it is undeniably a superior experience."
"The response to our products and technology has been overwhelming, and we are very excited to continue this success in the largest nutraceutical and cannabis markets in the world through our partnership in Glow Lifetech. This has been a landmark time for our global expansion efforts with the signing of our partnership with MGC Pharmaceuticals in Australia to leverage our technology to develop anti-viral products and our continued rollout with Relay in North America," said Michel Faessler.
Initial product line
The technology allows Glow to formulate cannabinoids and nutraceuticals with dramatically improved absorption, fast-acting onset, precise dosing and superior health benefits, using all-natural ingredients, to meet the growing demands for next-generation value-add products.
Glow LifeTech's initial focus is to bring the technology's most popular, natural and relevant enhanced bio-active vitamins, supplements and cannabis compounds to the North American marketplace. Glow will offer pure and hybrid products as part of commercialization efforts, subject to relevant legal and regulatory requirements in applicable jurisdictions.
Curcumin
Curcumin is the bio-active substance found in turmeric, which has poor bio-availability on its own and therefore requires special formulations to be properly absorbed. Modern scientific research has demonstrated its anti-inflammatory, antioxidant, anti-carcinogenic, anti-thrombotic and cardiovascular protective effects. Harvard Health, along with many other institutions, sees inflammation at the centre of disease management today. The curcumin market is set for significant 12.3 per cent compound annual growth rate and to exceed $100-million in North America by 2025, and with multinational brands like Starbucks Coffee already offering infused drinks with curcumin, the market forecast could outperform these expectations.
Immune Boost C-O-C (curcumin-olibanum-vitamin-C)
Vitamin C is widely known to have immune-boosting properties, along with tissue repair and supporting collagen formation. The essential oil olibanum, commonly know as frankincense, has been found to have cardio-protective benefits, studied for treatment as an anti-microbial, anti-inflammatory, anti-oxidant and to support liver function.
The powerful combination of curcumin, olibanum and vitamin C is expected to have anti-inflammatory and immune system benefits. The market size for this novel formulation the company believes to be substantial and poised for growth amidst cold and flu seasons and the current COVID-19 crisis, as it is imperative that people continue to support their immune systems.
Cannabidiol (CBD) and other cannabis products
CBD has been used as a natural pain reliever derived from the marijuana plant since 2900 B.C. The legalization has brought to light many other potential benefits for anxiety and pain management.
The growth and utility of CBD is expansive with a CAGR of over 105 per cent, the United States market alone is set to reach $23.7-billion by 2023. Glow LifeTech will navigate the marketplace and offer CBD and tetrahydrocannabinol products to legal jurisdictions, and will abide by all local and federal laws surrounding the selling and handling of cannabis-based products.
Iron
Iron therapies and supplementation have been essential in reducing the prevalence of widespread anemia in the population. Studies show the efficacy for anemia prevention in pregnant women, who can be at significantly higher risk of developing an iron deficiency. In addition, iron supplements can support those who take iron-depleting medications prescribed by their doctors.
The vitamins and dietary supplements market size was $37-billion in 2016 and is set to reach $68-billion by 2025. Although iron is only a subset of this marketplace, it has proven to be timeless and essential, and is one that will continue to foster strong growth and demand going forward. In partnership with Swiss PharmaCan, Glow will continue product development, research and studies to bring a novel iron supplement to the North American market.
Request a free sample
As a celebration of the joint venture partnership, the companies are giving 1,000 European consumers the exclusive opportunity to experience a sample of the products ahead of Glow's North American launch. Interested parties can request a sample at Glow's website
About Relay Medical Corp.
Relay Medical is a medical technology innovation company headquartered in Toronto, Canada, focused on the development of novel technologies in the diagnostics and data science sectors.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.